| pathology | Benefit (demonstrated or suggested) and harm | | | |
|---|
| acute myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Bussman, 1984 | vs control | | | all cause death NaN [NaN; NaN] confirmed myocardial infarction 1.00 [1.00; 1.00] | | DAVIT I, 1984 | vs control | | | | | Crea, 1985 | vs control | | | all cause death 0.00 [0.00; NaN] confirmed myocardial infarction 1.00 [1.00; 1.00] | | DAVIT II, 1990 | vs control | | | all cause death 0.82 [0.63; 1.05] cardiac death 0.80 [0.61; 1.05] | | CRIS, 1996 | vs control | | | all cause death 1.06 [0.64; 1.73] cardiac death 0.97 [0.54; 1.75] reinfarction 0.81 [0.54; 1.22] | | Danish study, 1984 | vs control | | | confirmed myocardial infarction 0.99 [0.92; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| Bussman, 1984 | Verapamil 5 to 10 mg/h IV (n=29) vs. no treatment (n=25) | | open Parallel groups Sample size: 29/25 Primary endpoint: infract size FU duration: 2 days | | DAVIT I, 1984 | verapamil 120mgx3 (n=1751) vs. placebo (n=1747) | | Double blind Parallel groups Sample size: 1751/1747 Primary endpoint: all-cause mortality FU duration: 6 months | | Crea, 1985 | verapamil 80mgx3 (n=8) vs. placebo (n=9) | patients admitted to the coronary care unit with transmural acute myocardial infarction | single blind Parallel groups Sample size: 8/9 Primary endpoint: angina and reinfarction FU duration: 10 days | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months (n=878) vs. placebo (n=897) | patients <76years with diagnosis of acute MI | Double blind Parallel groups Sample size: 878/897 Primary endpoint: all-cause mortality and firstmajor event FU duration: 16 months | | CRIS, 1996 | verapamil retard 360 mg daily (n=531) vs. placebo (n=542) | patients admitted for acute myocardial infarction | Double blind Parallel groups Sample size: 531/542 Primary endpoint: all-cause mortality FU duration: 23.5 months | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729) vs. placebo (n=1718) | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction | double blind Parallel groups Sample size: 1729/1718 Primary endpoint: mortality FU duration: 12 months |
|
| hypertension | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| VHAS, 1998 | vs chlorthalidone | | | all cause death 1.25 [0.34; 4.64] coronary heart disease 0.90 [0.37; 2.20] cardiovascular death 1.25 [0.34; 4.64] fatal MI 0.75 [0.17; 3.34] heart failure ∞ [NaN; ∞] fatal stroke ∞ [NaN; ∞] non fatal stroke 0.75 [0.17; 3.34] non fatal MI 1.00 [0.29; 3.44] stroke (fatal & non fatal) 1.25 [0.34; 4.64] Major cardiovascular events 1.07 [0.52; 2.20] | | CONVINCE, 2003 | vs chlorthalidone | | | all cause death 1.07 [0.92; 1.25] coronary heart disease 0.81 [0.65; 1.02] cardiovascular death 1.08 [0.86; 1.35] stroke (fatal & non fatal) 0.81 [0.65; 1.02] Major cardiovascular events 1.01 [0.88; 1.17] | | INVEST (Pepine), 2003 | vs chlorthalidone | | | all cause death 0.98 [0.90; 1.07] non fatal stroke 0.89 [0.70; 1.12] non fatal MI 0.99 [0.79; 1.24] |
| Trial | Treatments | Patients | Method |
|---|
| VHAS, 1998 | verapamil SR 240 mg/d (n=707) vs. chlorthalidone 25mg/d (n=707) | HBP | Open Parallel groups Sample size: 707/707 Primary endpoint: Not given FU duration: 2 years | | CONVINCE, 2003 | controlled-onset extendedrelease(COER) verapamil 180mg/d (n=8241) vs. hydrochlorothiazide 12.5 mg/d or atenolol 50 mg/d(investigator choice prior to randomization) (n=8361) | hypertension with 1 or more additional risk factors for cardiovascular disease | Double blind Parallel groups Sample size: 8241/8361 Primary endpoint: FU duration: 3 y | | INVEST (Pepine), 2003 | verapamil sustained release 240mg/d (n=11267) vs. atenolol 50mg/d (n=11309) | patients with hypertension and CAD | Sample size: 11267/11309 Primary endpoint: FU duration: 2.7 y |
|
| percutaneous coronary intervention | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Hoberg, 1994 | vs placebo | | | restenosis 0.77 [0.59; 1.01] |
| Trial | Treatments | Patients | Method |
|---|
| Hoberg, 1994 | verapamil (240 mg bid) (n=89) vs. placebo (n=83) | | double blind Sample size: 89/83 Primary endpoint: FU duration: 6 months |
|
| post myocardial infarction | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| DAVIT I, 1984 | vs placebo | | | | | DAVIT II, 1990 | vs placebo | | | all cause death 0.82 [0.63; 1.05] cardiac death 0.80 [0.61; 1.05] | | CRIS, 1996 | vs placebo | | | all cause death 1.06 [0.64; 1.73] cardiac death 0.97 [0.54; 1.75] reinfarction 0.81 [0.54; 1.22] | | Danish study, 1984 | vs placebo | | | confirmed myocardial infarction 0.99 [0.92; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| DAVIT I, 1984 | verapamil 120mgx3 (n=1751) vs. placebo (n=1747) | | Double blind Parallel groups Sample size: 1751/1747 Primary endpoint: all-cause mortality FU duration: 6 months | | DAVIT II, 1990 | verapamil 120mgx3 for 18 months (n=878) vs. placebo (n=897) | patients <76years with diagnosis of acute MI | Double blind Parallel groups Sample size: 878/897 Primary endpoint: all-cause mortality and firstmajor event FU duration: 16 months | | CRIS, 1996 | verapamil retard 360 mg daily (n=531) vs. placebo (n=542) | patients admitted for acute myocardial infarction | Double blind Parallel groups Sample size: 531/542 Primary endpoint: all-cause mortality FU duration: 23.5 months | | Danish study, 1984 | verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729) vs. placebo (n=1718) | patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction | double blind Parallel groups Sample size: 1729/1718 Primary endpoint: mortality FU duration: 12 months |
|
